دورية أكاديمية
أعرض في EDS

Causal association between lipid-lowering drugs and cancers: A drug target Mendelian randomization study.

التفاصيل البيبلوغرافية
العنوان: Causal association between lipid-lowering drugs and cancers: A drug target Mendelian randomization study.
المؤلفون: Ding W; The Second Clinical Medical School, Anhui University of Chinese Medicine, Hefei, Anhui, China., Chen L; Department of Gastroenterology, The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, China., Xia J; Department of Gastroenterology, The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, China., Pei B; The Second Clinical Medical School, Anhui University of Chinese Medicine, Hefei, Anhui, China., Song B; Department of Gastroenterology, The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, China., Li X; Department of Gastroenterology, The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, China.
المصدر: Medicine [Medicine (Baltimore)] 2024 May 03; Vol. 103 (18), pp. e38010.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Mendelian Randomization Analysis* , Neoplasms*/genetics , Neoplasms*/epidemiology , Hydroxymethylglutaryl CoA Reductases*/genetics , Polymorphism, Single Nucleotide* , Proprotein Convertase 9*, Humans ; Female ; PCSK9 Inhibitors ; Hypolipidemic Agents/therapeutic use ; Male ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
مستخلص: Accumulating evidences have indicated that lipid-lowering drugs have effect for the treatment of cancers. However, causal associations between lipid-lowering drugs and the risk of cancers are still unclear. In our study, we utilized single nucleotide polymorphisms of proprotein convertase subtilis kexin 9 (PCSK9) inhibitors and 3-hydroxy-3-methylglutaryl-assisted enzyme A reductase (HMGCR) inhibitors and performed a drug target Mendelian randomization to explore the causal association between lipid-lowering drugs and the risk of cancers. Five regression methods were carried out, including inverse variance weighted (IVW) method, MR Egger, weighted median, simple mode and weighted mode methods, of which IVW method was considered as the main analysis. Our outcome dataset contained the risk of breast cancer (BC), colorectal cancer, endometrial cancer, gastric cancer (GC), hepatocellular carcinoma (HCC), lung cancer, esophageal cancer, prostate cancer (PC), and skin cancer (SC). Our results demonstrated that PCSK9 inhibitors were significant associated with a decreased effect of GC [IVW: OR = 0.482, 95% CI: 0.264-0.879, P = .017]. Besides, genetic inhibitions of HMGCR were significant correlated with an increased effect of BC [IVW: OR = 1.421, 95% CI: 1.056-1.911, P = .020], PC [IVW: OR = 1.617, 95% CI: 1.234-2.120, P = .0005] and SC [IVW: OR = 1.266, 95% CI: 1.022-1.569, P = .031]. For GC [IVW: OR = 0.559, 95% CI: 0.382-0.820, P = .0029] and HCC [IVW: OR = 0.241, 95% CI: 0.085-0.686, P = .0077], HMGCR inhibitors had a protective risk. Our method suggested that PCSK9 inhibitors were significant associated with a protective effect of GC. Genetic inhibitions of HMGCR were significant correlated with an increased effect of BC, PC and SC. Meanwhile, HMGCR inhibitors had a protective risk of GC and HCC. Subsequent studies still needed to assess potential effects between lipid-lowering drugs and the risk of cancers with clinical trials.
Competing Interests: The authors have no conflicts of interest to disclose.
(Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
References: Genet Epidemiol. 2013 Nov;37(7):658-65. (PMID: 24114802)
Int J Dermatol. 2023 Nov;62(11):1332-1344. (PMID: 37681467)
J Pharmacol Exp Ther. 2011 Feb;336(2):496-505. (PMID: 21059805)
N Engl J Med. 2019 Oct 17;381(16):1547-1556. (PMID: 31618540)
Exp Ther Med. 2017 May;13(5):1993-1999. (PMID: 28565798)
Arch Med Sci. 2019 May;15(3):559-569. (PMID: 31110520)
Front Oncol. 2021 Aug 24;11:708039. (PMID: 34504788)
PLoS Med. 2023 Jan 3;20(1):e1003988. (PMID: 36595504)
Int J Epidemiol. 2015 Apr;44(2):512-25. (PMID: 26050253)
Nat Rev Cancer. 2022 May;22(5):280-297. (PMID: 35102280)
Arthritis Res Ther. 2023 Aug 14;25(1):148. (PMID: 37580807)
Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7797-802. (PMID: 10393901)
Eur J Cancer. 2008 Oct;44(15):2122-32. (PMID: 18707867)
Cancer Res Treat. 2021 Apr;53(2):445-456. (PMID: 33253515)
J Natl Cancer Inst. 2011 Mar 16;103(6):508-19. (PMID: 21285406)
Genet Epidemiol. 2016 May;40(4):304-14. (PMID: 27061298)
Expert Rev Proteomics. 2007 Apr;4(2):239-48. (PMID: 17425459)
Cancer Cell. 2010 Apr 13;17(4):348-61. (PMID: 20385360)
Cochrane Database Syst Rev. 2017 Apr 28;4:CD011748. (PMID: 28453187)
Breast Cancer Res Treat. 2013 Apr;138(2):499-508. (PMID: 23471651)
Cancers (Basel). 2021 Jul 24;13(15):. (PMID: 34359627)
Nat Commun. 2020 Jun 26;11(1):3255. (PMID: 32591531)
Biomed Pharmacother. 2021 Aug;140:111758. (PMID: 34058443)
Cancer Biol Med. 2021 Apr 24;:. (PMID: 33893729)
Front Oncol. 2023 Sep 06;13:1251873. (PMID: 37746259)
Cancers (Basel). 2022 Dec 20;15(1):. (PMID: 36612001)
Int J Epidemiol. 2017 Dec 1;46(6):1985-1998. (PMID: 29040600)
BMC Gastroenterol. 2015 Dec 16;15:176. (PMID: 26674961)
Gene. 2016 Aug 1;587(1):42-7. (PMID: 27085483)
Nat Rev Cancer. 2005 Dec;5(12):930-42. (PMID: 16341084)
Elife. 2018 May 30;7:. (PMID: 29846171)
Front Oncol. 2021 Jan 07;10:609663. (PMID: 33489919)
Int J Cancer. 2021 Apr 5;:. (PMID: 33818764)
N Engl J Med. 2017 May 4;376(18):1713-1722. (PMID: 28304224)
Mol Carcinog. 2001 Nov;32(3):154-66. (PMID: 11746827)
Eur J Pharmacol. 2011 Nov 30;670(2-3):356-64. (PMID: 21958871)
Nat Rev Cardiol. 2017 Nov;14(11):635-636. (PMID: 28980665)
Clin Cancer Res. 2004 Dec 15;10(24):8648-55. (PMID: 15623649)
Breast Cancer Res. 2022 Feb 12;24(1):12. (PMID: 35151363)
Int J Cancer. 2008 Feb 15;122(4):909-14. (PMID: 17957783)
J Clin Oncol. 2011 Apr 20;29(12):1592-8. (PMID: 21422422)
Lancet. 1991 Jun 22;337(8756):1529-31. (PMID: 1675380)
Gynecol Oncol. 2014 Aug;134(2):346-55. (PMID: 24880141)
Lancet. 2020 Aug 29;396(10251):635-648. (PMID: 32861308)
Nat Commun. 2018 Sep 27;9(1):3957. (PMID: 30262900)
J Cancer Epidemiol. 2012;2012:792034. (PMID: 22969802)
PLoS One. 2011;6(12):e28813. (PMID: 22216116)
Lancet Diabetes Endocrinol. 2017 Feb;5(2):97-105. (PMID: 27908689)
Stat Med. 2015 Sep 20;34(21):2926-40. (PMID: 25950993)
المشرفين على المادة: EC 1.1.1.- (Hydroxymethylglutaryl CoA Reductases)
EC 1.1.1.- (HMGCR protein, human)
EC 3.4.21.- (PCSK9 protein, human)
0 (PCSK9 Inhibitors)
0 (Hypolipidemic Agents)
0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
EC 3.4.21.- (Proprotein Convertase 9)
تواريخ الأحداث: Date Created: 20240503 Date Completed: 20240503 Latest Revision: 20240507
رمز التحديث: 20240507
مُعرف محوري في PubMed: PMC11062692
DOI: 10.1097/MD.0000000000038010
PMID: 38701318
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000038010